Proliferation of DU145 prostate cancer cells is inhibited by suppressing insulin-like growth factor binding protein-2
Article first published online: 12 OCT 2004
International Journal of Urology
Volume 11, Issue 10, pages 876–884, October 2004
How to Cite
CHATTERJEE, S., PARK, E. S. and SOLOFF, M. S. (2004), Proliferation of DU145 prostate cancer cells is inhibited by suppressing insulin-like growth factor binding protein-2. International Journal of Urology, 11: 876–884. doi: 10.1111/j.1442-2042.2004.00898.x
- Issue published online: 12 OCT 2004
- Article first published online: 12 OCT 2004
- Received 16 June 2003; accepted 17 February 2004.
- IGFBP-2 suppression;
- growth inhibition;
- prostate cancer.
Background: Insulin-like growth factor binding protein-2 (IGFBP-2) is expressed by all human prostate cancer cell lines and dramatically increases in the serum of prostate cancer patients. However, the role of IGFBP-2 in prostatic tumorigenesis is not known. The aim of the present study was to investigate the effects of IGFBP-2 on the proliferation of DU145 human prostate cancer cells in culture.
Methods: Using cell proliferation assays, we examined the effects of exogenously administered and endogenously modulated levels of IGFBP-2 on the proliferation of DU145 cells.
Result: Cell growth was stimulated by exogenously administered IGFBP-2, but significantly retarded (P < 0.05) by its neutralizing antibody. Overexpression of IGFBP-2 by transfection also stimulated cell growth, which was significantly (P < 0.05) inhibited in transfectants expressing antisense mRNA to IGFBP-2. Furthermore, the proliferation of IGFBP-2 overexpressing cells was significantly dampened by exogenously administered IGFBP-2 antibody.
Conclusions: IGFBP-2 is an autocrine growth factor for DU145 human prostate cancer cells and cell proliferation can be significantly retarded by neutralizing or inhibiting its synthesis. These findings provide a strong rationale for targeting IGFBP-2 in the testing of novel strategies to treat prostate cancer.